Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    BusinessNewsAsia.comBusinessNewsAsia.com
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    BusinessNewsAsia.comBusinessNewsAsia.com
    Home»BioTech»Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU
    BioTech

    Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU

    Marie JonesBy Marie JonesAugust 18, 2022Updated:August 22, 2022No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Parties to look for collaborations in practice-based education, research and knowledge exchange and R&D

    Malaysian Genomics Resource Centre Berhad‘s (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.

    En. Azri Azerai, Executive Director of Malaysian Genomics
    Datin Dr Maya, Chief Executive Officer of MAHSA Health

    Malaysian Genomics is the first company in Malaysia to pioneer genomics and genetic screening in Malaysia for over 17 years. Since then, Malaysian Genomics has expanded its offerings in other important areas in the healthcare and wellness that include cancer immunotherapy, cell manufacturing services and kidney dialysis. Malaysian Genomics continues to strive to provide the latest in precautionary, preventive and curative healthcare services for its local and worldwide customers.

    MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare. Since its inception in 2017, MAHSA Health has been striving to be in the forefront of primary healthcare, focusing on family health and wellness.

    Encik Azri Azerai, Executive Directorof Malaysian Genomics said, “We look forward to sharing our experience in genomics, bioinformatics, and biopharmaceuticals with MAHSA Health via this collaboration. By providing industry inputs and insights to MAHSA, we hope to benefit students at MAHSA with the tremendous promise that various healthcare sciences have to offer for all.”

    “Through this collaboration we also hope to identify opportunities to improve the delivery of integrated, holistic primary healthcare services, including genetic screening services to improve the lives of individuals in the long run.”

    Datin Dr Maya, CEO of MAHSA Health, with her double expertise in health and wellness services, and education industry, said, “Passion is the greatest asset we each have. The main idea of MAHSA Health is to improve the quality of life in providing health care and wellness services to our community. We are a team-based healthcare that provides comprehensive medical care to patients with the goal of obtaining maximized health outcomes.”

    “Through this collaboration, we foresee opportunities and collaborative efforts in many areas, both in health care and education industry in providing an ecosystem of teaching, training, and producing services to the country nationwide.”

    The MoU is a framework through which MGRC Therapeutics and MAHSA Health can explore opportunities for health and wellness-related services; create opportunities for students’ clinical placement, internship and employment; identify opportunities for conducting collaborative research and development (R&D); and create opportunities in training, seminars and conferences.

    Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/

    Malaysian Genomics Resource Centre Berhad
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleHektar REIT Sustainability & CSR Initiatives Gets Awarded
    Next Article BitKeep Releases Its V 7.1.5

    Related Posts

    Accrelist Appoints Derek Cheong as Chief Executive Officer

    June 17, 2026

    Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

    June 16, 2026

    Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

    June 9, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.